Table 4.
Outcomes of 30d follow‐up
| TTE | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Mortality | MI | Stroke | New pacemaker | Indexed EOA (cm2/m2) | PPM | NYHA class | AVA (cm2) | PGmean (mm Hg) | V max (m/s) | LVEF (%) | PVL grade (0–3) |
| 1 | 0 | 0 | 0 | 0 | 1.02 | Insignificant | III | 1.35 | 8 | 1.97 | 40.0 | 0 |
| 2 | 0 | 0 | 0 | 0 | 0.98 | Insignificant | I | 1.89 | 18 | 2.97 | 65.0 | 1 |
| 3 | 0 | 0 | 0 | 0 | 1.46 | Insignificant | III | 2.3 | 10 | 2.30 | 29.2 | 1 |
| 4 | 0 | 0 | 0 | 0 | 0.78 | Moderate | II | 1.35 | 16 | 2.70 | 48.0 | 1 |
| 5 | 0 | 0 | 0 | 0 | 0.94 | Insignificant | II | 1.57 | 9 | 2.22 | 59.7 | 1 |
| 6 | 0 | 0 | 1 (non‐disabling) | 0 | 1.17 | Insignificant | II | 1.98 | 9 | 2.21 | 60.1 | 0 |
| 7 | 0 | 0 | 0 | 0 | 1.08 | Insignificant | II | 1.84 | 6 | 1.65 | 59.8 | 1 |
| 8 | 0 | 0 | 0 | 0 | 0.81 | Moderate | I | 1.20 | 16 | 3.00 | 69.1 | 0 |
| 9 | 0 | 0 | 0 | 0 | 0.90 | Insignificant | II | 1.56 | 8 | 2.10 | 62.1 | 1 |
| 10 | 0 | 0 | 0 | 0 | 0.82 | Moderate | I | 1.76 | 10 | 2.15 | 66.1 | 0 |
| 11 | 0 | 0 | 0 | 0 | 0.85 | Insignificant | II | 1.20 | 12 | 2.50 | 68.1 | 1 |
| 12 | 0 | 0 | 0 | 0 | 0.87 | Insignificant | II | 1.60 | 11 | 2.40 | 58.0 | 1 |
Abbreviations: AVA, aortic valve area; EOA, effective orifice area; LVEF, left ventricle ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PGmean, mean pressure gradient; PPM, prosthesis‐patient mismatch; PVL, paravalvular leakage; TTE, transthoracic echocardiography; Vmax, maximum velocity.